

Masafumi Takiguchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6471019/publications.pdf>

Version: 2024-02-01

119
papers

4,758
citations

117453

34
h-index

106150

65
g-index

121
all docs

121
docs citations

121
times ranked

5001
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of Micropolymorphism Outside the Peptide Binding Groove in the Clinically Relevant Allele HLA-C*14 on T Cell Responses in HIV-1 Infection. <i>Journal of Virology</i> , 2022, 96, e0043222.	1.5	2
2	Effect of Difference in Consensus Sequence between HIV-1 Subtype A/E and Subtype B Viruses on Elicitation of Gag-Specific CD8 ⁺ T Cells and Accumulation of HLA-Associated Escape Mutations. <i>Journal of Virology</i> , 2021, 95, .	1.5	4
3	STING Ligand-Mediated Priming of Functional CD8 ⁺ T Cells Specific for HIV-1-Protective Epitopes from Naive T Cells. <i>Journal of Virology</i> , 2021, 95, e0069921.	1.5	1
4	Collaboration of a detrimental HLA-B*35:01 allele with HLA-A*24:02 in co-evolution of HIV-1 with T-cells leading to poorer clinical outcomes. <i>Journal of Virology</i> , 2021, 95, e0125921.	1.5	2
5	Critical effect of Pol escape mutations associated with detrimental allele HLA-C*15:05 on clinical outcome in HIV-1 subtype A/E infection. <i>Aids</i> , 2021, 35, 33-43.	1.0	3
6	Determination of a T cell receptor of potent CD8 ⁺ T cells against simian immunodeficiency virus infection in Burmese rhesus macaques. <i>Biochemical and Biophysical Research Communications</i> , 2020, 521, 894-899.	1.0	4
7	Role of Escape Mutant-Specific T Cells in Suppression of HIV-1 Replication and Coevolution with HIV-1. <i>Journal of Virology</i> , 2020, 94, .	1.5	5
8	Specificity of CD8 ⁺ T-Cell Responses Following Vaccination with Conserved Regions of HIV-1 in Nairobi, Kenya. <i>Vaccines</i> , 2020, 8, 260.	2.1	5
9	Novel Nested Peptide Epitopes Recognized by CD4 ⁺ T Cells Induced by HIV-1 Conserved-Region Vaccines. <i>Vaccines</i> , 2020, 8, 28.	2.1	8
10	Existence of Replication-Competent Minor Variants with Different Coreceptor Usage in Plasma from HIV-1-Infected Individuals. <i>Journal of Virology</i> , 2020, 94, .	1.5	9
11	T-cell responses to sequentially emerging viral escape mutants shape long-term HIV-1 population dynamics. <i>PLoS Pathogens</i> , 2020, 16, e1009177.	2.1	4
12	Title is missing!. , 2020, 16, e1009177.		0
13	Title is missing!. , 2020, 16, e1009177.		0
14	Title is missing!. , 2020, 16, e1009177.		0
15	Title is missing!. , 2020, 16, e1009177.		0
16	Effective Suppression of HIV-1 Replication by Cytotoxic T Lymphocytes Specific for Pol Epitopes in Conserved Mosaic Vaccine Immunogens. <i>Journal of Virology</i> , 2019, 93, .	1.5	26
17	Identification of Immunodominant HIV-1 Epitopes Presented by HLA-C*12:02, a Protective Allele, Using an Immunopeptidomics Approach. <i>Journal of Virology</i> , 2019, 93, .	1.5	11
18	Priming of HIV-1-specific CD8 ⁺ T cells with strong functional properties from naïve T cells. <i>EBioMedicine</i> , 2019, 42, 109-119.	2.7	15

#	ARTICLE	IF	CITATIONS
19	Contribution of proteasome-catalyzed peptide cis-splicing to viral targeting by CD8 ⁺ T cells in HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 24748-24759.	3.3	48
20	Broad Recognition of Circulating HIV-1 by HIV-1-Specific Cytotoxic T-Lymphocytes with Strong Ability to Suppress HIV-1 Replication. Journal of Virology, 2019, 93, .	1.5	15
21	The STING ligand cGAMP potentiates the efficacy of vaccine-induced CD8 ⁺ T cells. JCI Insight, 2019, 4, .	2.3	72
22	HLA Class I-Mediated HIV-1 Control in Vietnamese Infected with HIV-1 Subtype A/E. Journal of Virology, 2018, 92, .	1.5	16
23	Impact of a single HLA-A*24:02-associated escape mutation on the detrimental effect of HLA-B*35:01 in HIV-1 control. EBioMedicine, 2018, 36, 103-112.	2.7	10
24	Identification of novel HIV-1-derived HLA-E-binding peptides. Immunology Letters, 2018, 202, 65-72.	1.1	21
25	CD8 ⁺ T cells specific for conserved, cross-reactive Gag epitopes with strong ability to suppress HIV-1 replication. Retrovirology, 2018, 15, 46.	0.9	37
26	Accumulation of Pol Mutations Selected by HLA-B*52:01-C*12:02 Protective Haplotype-Restricted Cytotoxic T Lymphocytes Causes Low Plasma Viral Load Due to Low Viral Fitness of Mutant Viruses. Journal of Virology, 2017, 91, .	1.5	17
27	Control of HIV-1 by an HLA-B*52:01-C*12:02 Protective Haplotype. Journal of Infectious Diseases, 2017, 216, 1415-1424.	1.9	21
28	Novel, in-natural-infection subdominant HIV-1 CD8 ⁺ T-cell epitopes revealed in human recipients of conserved-region T-cell vaccines. PLoS ONE, 2017, 12, e0176418.	1.1	27
29	A strong association of human leukocyte antigen-associated Pol and Gag mutations with clinical parameters in HIV-1 subtype A/E infection. Aids, 2016, 30, 681-689.	1.0	18
30	HIV-1 Control by NK Cells via Reduced Interaction between KIR2DL2 and HLA-C ^α -12:02/C ^α -14:03. Cell Reports, 2016, 17, 2210-2220.	2.9	27
31	Effects of a Single Escape Mutation on T Cell and HIV-1 Co-adaptation. Cell Reports, 2016, 15, 2279-2291.	2.9	19
32	Rilpivirine resistance mutation E138K in HIV-1 reverse transcriptase predisposed by prevalent polymorphic mutations. Journal of Antimicrobial Chemotherapy, 2016, 71, 2760-2766.	1.3	6
33	Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection. Molecular Therapy, 2016, 24, 832-842.	3.7	107
34	TCR clonotypes: molecular determinants of T-cell efficacy against HIV. Current Opinion in Virology, 2016, 16, 77-85.	2.6	18
35	Lack of a significant impact of Gag-Protease-mediated HIV-1 replication capacity on clinical parameters in treatment-naive Japanese individuals. Retrovirology, 2015, 12, 98.	0.9	4
36	Different Effects of Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Cytotoxic T Lymphocyte Recognition between HIV-1 Subtype B and Subtype A/E Infections. Journal of Virology, 2015, 89, 7363-7372.	1.5	5

#	ARTICLE	IF	CITATIONS
37	Clinical Control of HIV-1 by Cytotoxic T Cells Specific for Multiple Conserved Epitopes. <i>Journal of Virology</i> , 2015, 89, 5330-5339.	1.5	56
38	Fibrocytes Differ from Macrophages but Can Be Infected with HIV-1. <i>Journal of Immunology</i> , 2015, 195, 4341-4350.	0.4	12
39	V3-Independent Competitive Resistance of a Dual-X4 HIV-1 to the CXCR4 Inhibitor AMD3100. <i>PLoS ONE</i> , 2014, 9, e89515.	1.1	2
40	Selection of T18-8V Mutant Associated with Long-Term Control of HIV-1 by Cross-Reactive HLA-B*51:01-Restricted Cytotoxic T Cells. <i>Journal of Immunology</i> , 2014, 193, 4814-4822.	0.4	11
41	Raltegravir and elvitegravir-resistance mutation E92Q affects HLA-B*40:02-restricted HIV-1-specific CTL recognition. <i>Microbes and Infection</i> , 2014, 16, 434-438.	1.0	1
42	Superimposed Epitopes Restricted by the Same HLA Molecule Drive Distinct HIV-Specific CD8+ T Cell Repertoires. <i>Journal of Immunology</i> , 2014, 193, 77-84.	0.4	15
43	Host-Specific Adaptation of HIV-1 Subtype B in the Japanese Population. <i>Journal of Virology</i> , 2014, 88, 4764-4775.	1.5	47
44	Molecular Basis of a Dominant T Cell Response to an HIV Reverse Transcriptase 8-mer Epitope Presented by the Protective Allele HLA-B*51:01. <i>Journal of Immunology</i> , 2014, 192, 3428-3434.	0.4	25
45	Identification of cross-clade CTL epitopes in HIV-1 clade A/E-infected individuals by using the clade B overlapping peptides. <i>Microbes and Infection</i> , 2013, 15, 874-886.	1.0	15
46	Early Antigen Presentation of Protective HIV-1 KF11Gag and KK10Gag Epitopes from Incoming Viral Particles Facilitates Rapid Recognition of Infected Cells by Specific CD8 ⁺ T Cells. <i>Journal of Virology</i> , 2013, 87, 2628-2638.	1.5	40
47	A Molecular Basis for the Control of Preimmune Escape Variants by HIV-Specific CD8+ T Cells. <i>Immunity</i> , 2013, 38, 425-436.	6.6	149
48	Naturally Selected Rilpivirine-Resistant HIV-1 Variants by Host Cellular Immunity. <i>Clinical Infectious Diseases</i> , 2013, 57, 1051-1055.	2.9	22
49	Distinct HIV-1 Escape Patterns Selected by Cytotoxic T Cells with Identical Epitope Specificity. <i>Journal of Virology</i> , 2013, 87, 2253-2263.	1.5	30
50	HLA Class I-Mediated Control of HIV-1 in the Japanese Population, in Which the Protective HLA-B*57 and HLA-B*27 Alleles Are Absent. <i>Journal of Virology</i> , 2012, 86, 10870-10872.	1.5	40
51	Selection and Accumulation of an HIV-1 Escape Mutant by Three Types of HIV-1-Specific Cytotoxic T Lymphocytes Recognizing Wild-Type and/or Escape Mutant Epitopes. <i>Journal of Virology</i> , 2012, 86, 1971-1981.	1.5	15
52	Differential Clade-Specific HLA-B*3501 Association with HIV-1 Disease Outcome Is Linked to Immunogenicity of a Single Gag Epitope. <i>Journal of Virology</i> , 2012, 86, 12643-12654.	1.5	49
53	CTL recognition of HIV-1-infected cells via cross-recognition of multiple overlapping peptides from a single 11-mer P-loop sequence. <i>European Journal of Immunology</i> , 2012, 42, 2621-2631.	1.6	5
54	Unbiased Analysis of TCR β Chains at the Single-Cell Level in Human CD8+ T-Cell Subsets. <i>PLoS ONE</i> , 2012, 7, e40386.	1.1	31

#	ARTICLE	IF	CITATIONS
55	Effective Elicitation of Human Effector CD8+ T Cells in HLA-B*51:01 Transgenic Humanized Mice after Infection with HIV-1. PLoS ONE, 2012, 7, e42776.	1.1	15
56	Functional heterogeneity of human effector CD8+ T cells. Blood, 2012, 119, 1390-1398.	0.6	18
57	Escape from highly effective public CD8+ T-cell clonotypes by HIV. Blood, 2011, 118, 2138-2149.	0.6	103
58	Selection of escape mutant by HLA-B*51-restricted HIV-1 Pol-specific cytotoxic T lymphocytes carrying strong ability to suppress HIV-1 replication. European Journal of Immunology, 2011, 41, 97-106.	1.6	26
59	Effective recognition of HIV-1-infected cells by HIV-1 integrase-specific HLA-B*4002-restricted T cells. Microbes and Infection, 2011, 13, 160-166.	1.0	10
60	Selection of HLA-B57-associated Gag A146P mutant by HLA-B*48:01-restricted Gag140-147-specific CTLs in chronically HIV-1-infected Japanese. Microbes and Infection, 2011, 13, 766-770.	1.0	3
61	Multilayered Defense in HLA-B51-Associated HIV Viral Control. Journal of Immunology, 2011, 187, 684-691.	0.4	49
62	Impact of human leukocyte antigen-B*51-restricted cytotoxic T-lymphocyte pressure on mutation patterns of nonnucleoside reverse transcriptase inhibitor resistance. Aids, 2010, 24, F15-F22.	1.0	13
63	Comparison of CD4+ T-cell subset distribution in chronically infected HIV+ patients with various CD4 nadir counts. Microbes and Infection, 2010, 12, 374-381.	1.0	12
64	Different <i>In Vivo</i> Effects of HIV-1 Immunodominant Epitope-Specific Cytotoxic T Lymphocytes on Selection of Escape Mutant Viruses. Journal of Virology, 2010, 84, 5508-5519.	1.5	12
65	Long-Term Control of HIV-1 in Hemophiliacs Carrying Slow-Progressing Allele HLA-B*5101. Journal of Virology, 2010, 84, 7151-7160.	1.5	42
66	Selection of escape mutation by Pol154-162-specific cytotoxic T cells among chronically HIV-1-infected HLA-B*5401-positive individuals. Human Immunology, 2010, 71, 123-127.	1.2	2
67	Failure of Effector Function of Human CD8+ T Cells in NOD/SCID/JAK3 ^{-/-} Immunodeficient Mice Transplanted with Human CD34+ Hematopoietic Stem Cells. PLoS ONE, 2010, 5, e13109.	1.1	14
68	Cutting Edge: Phenotypic Characterization and Differentiation of Human CD8+ T Cells Producing IL-17. Journal of Immunology, 2009, 182, 1794-1798.	0.4	153
69	Human memory CCR4+CD8+ T cell subset has the ability to produce multiple cytokines. International Immunology, 2009, 21, 523-532.	1.8	38
70	Strong Ability of Nef-Specific CD4 ⁺ Cytotoxic T Cells To Suppress Human Immunodeficiency Virus Type 1 (HIV-1) Replication in HIV-1-Infected CD4 ⁺ T Cells and Macrophages. Journal of Virology, 2009, 83, 7668-7677.	1.5	40
71	Impact of Intrinsic Cooperative Thermodynamics of Peptide-MHC Complexes on Antiviral Activity of HIV-Specific CTL. Journal of Immunology, 2009, 182, 5528-5536.	0.4	14
72	Novel HIV-1 clade B candidate vaccines designed for HLA-B*5101 patients protected mice against chimaeric ecotropic HIV-1 challenge. European Journal of Immunology, 2009, 39, 1831-1840.	1.6	22

#	ARTICLE	IF	CITATIONS
73	Adaptation of HIV-1 to human leukocyte antigen class I. <i>Nature</i> , 2009, 458, 641-645.	13.7	408
74	Escape mutation selected by Gag28-36-specific cytotoxic T cells in HLA-A*2402-positive HIV-1-infected donors. <i>Microbes and Infection</i> , 2009, 11, 198-204.	1.0	7
75	Identification and characterization of 2 HIV-1 Gag immunodominant epitopes restricted by Asian HLA allele HLA-B*4801. <i>Human Immunology</i> , 2009, 70, 170-174.	1.2	5
76	HLA-A*2402-restricted HIV-1-specific cytotoxic T lymphocytes and escape mutation after ART with structured treatment interruptions. <i>Microbes and Infection</i> , 2008, 10, 689-698.	1.0	8
77	Different immunodominance of HIV-1-specific CTL epitopes among three subtypes of HLA-A*26 associated with slow progression to AIDS. <i>Biochemical and Biophysical Research Communications</i> , 2008, 366, 612-616.	1.0	7
78	Different Abilities of Escape Mutant-Specific Cytotoxic T Cells To Suppress Replication of Escape Mutant and Wild-Type Human Immunodeficiency Virus Type 1 in New Hosts. <i>Journal of Virology</i> , 2008, 82, 138-147.	1.5	32
79	CTL-Mediated Selective Pressure Influences Dynamic Evolution and Pathogenic Functions of HIV-1 Nef. <i>Journal of Immunology</i> , 2008, 180, 1107-1116.	0.4	57
80	Phenotypic classification of human CD4+ T cell subsets and their differentiation. <i>International Immunology</i> , 2008, 20, 1189-1199.	1.8	121
81	Altering Effects of Antigenic Variations in HIV-1 on Antiviral Effectiveness of HIV-Specific CTLs. <i>Journal of Immunology</i> , 2007, 178, 5513-5523.	0.4	33
82	HIV-1-specific CTLs effectively suppress replication of HIV-1 in HIV-1-infected macrophages. <i>Blood</i> , 2007, 109, 4832-4838.	0.6	34
83	Functional expression of chemokine receptor CCR6 on human effector memory CD8+ T cells. <i>European Journal of Immunology</i> , 2007, 37, 54-65.	1.6	52
84	Functional and phenotypic analysis of human memory CD8+ T cells expressing CXCR3. <i>Journal of Leukocyte Biology</i> , 2006, 80, 320-329.	1.5	25
85	Effects of Pathogens on the Immune Response: HIV. , 2006, , 209-231.		0
86	Three Memory Subsets of Human CD8+ T Cells Differently Expressing Three Cytolytic Effector Molecules. <i>Journal of Immunology</i> , 2006, 177, 4330-4340.	0.4	147
87	Patterns of Cytokine Production in Human Immunodeficiency Virus Type 1 (HIV-1)-Specific Human CD8 + T Cells after Stimulation with HIV-1-Infected CD4 + T Cells. <i>Journal of Virology</i> , 2005, 79, 12536-12543.	1.5	10
88	Cutting Edge: Epitope-Dependent Effect of Nef-Mediated HLA Class I Down-Regulation on Ability of HIV-1-Specific CTLs to Suppress HIV-1 Replication. <i>Journal of Immunology</i> , 2005, 174, 36-40.	0.4	51
89	Identification and characterization of HIV-1-specific CD8+ T cell epitopes presented by HLA-A*2601. <i>Vaccine</i> , 2005, 23, 3783-3790.	1.7	10
90	Cutting Edge: Expression of Chemokine Receptor CXCR1 on Human Effector CD8+ T Cells. <i>Journal of Immunology</i> , 2004, 173, 2231-2235.	0.4	70

#	ARTICLE	IF	CITATIONS
91	Phenotypic classification of human CD8+ T cells reflecting their function: inverse correlation between quantitative expression of CD27 and cytotoxic effector function. <i>European Journal of Immunology</i> , 2004, 34, 999-1010.	1.6	96
92	Down-regulation of CXCR4 expression on human CD8+ T cells during peripheral differentiation. <i>European Journal of Immunology</i> , 2004, 34, 3370-3378.	1.6	42
93	Identification and Characterization of HLA-A*3303-Restricted, HIV Type 1 Pol- and Gag-Derived Cytotoxic T Cell Epitopes. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 503-510.	0.5	14
94	Differentiation of Human CD8+ T Cells from a Memory to Memory/Effector Phenotype. <i>Journal of Immunology</i> , 2002, 168, 5538-5550.	0.4	201
95	Different Effects of Nef-Mediated HLA Class I Down-Regulation on Human Immunodeficiency Virus Type 1-Specific CD8 + T-Cell Cytolytic Activity and Cytokine Production. <i>Journal of Virology</i> , 2002, 76, 7535-7543.	1.5	77
96	Cytotoxic T-cell recognition of HIV-1 cross-clade and clade-specific epitopes in HIV-1-infected Thai and Japanese patients. <i>Aids</i> , 2002, 16, 701-711.	1.0	26
97	Single T Cell Receptor-Mediated Recognition of an Identical HIV-Derived Peptide Presented by Multiple HLA Class I Molecules. <i>Journal of Immunology</i> , 2002, 169, 4961-4969.	0.4	25
98	Identification of hepatitis B virus-specific CTL epitopes presented by HLA-A*2402, the most common HLA class I allele in East Asia. <i>Journal of Hepatology</i> , 2001, 34, 922-929.	1.8	57
99	Visual demonstration of hepatitis C virus-specific memory CD8+ T-cell expansion in patients with acute hepatitis C. <i>Hepatology</i> , 2001, 33, 287-294.	3.6	35
100	A single CTL clone can recognize a naturally processed HIV-1 epitope presented by two different HLA class I molecules. <i>European Journal of Immunology</i> , 2000, 30, 2521-2530.	1.6	24
101	Refined peptide HLA-B * 3501 binding motif reveals differences in 9-mer to 11-mer peptide binding. <i>Immunogenetics</i> , 1996, 45, 121-129.	1.2	18
102	Binding of nonamer peptides to three HLA-B51 molecules which differ by a single amino acid substitution in the A-pocket. <i>Immunogenetics</i> , 1996, 43, 268-276.	1.2	31
103	Role of strong anchor residues in the effective binding of 10-mer and 11-mer peptides to HLA-A*2402 molecules. <i>Immunogenetics</i> , 1996, 44, 233-241.	1.2	32
104	HLA AND ANTIGEN PEPTIDE. <i>Vox Sanguinis</i> , 1996, 70, 102-110.	0.7	0
105	An HLA-B35-restricted epitope modified at an anchor residue results in an antagonist peptide. <i>European Journal of Immunology</i> , 1996, 26, 335-339.	1.6	46
106	Binding of nonamer peptides to three HLA-B51 molecules which differ by a single amino acid substitution in the A-pocket. <i>Immunogenetics</i> , 1996, 43, 268-276.	1.2	7
107	Role of strong anchor residues in the effective binding of 10-mer and 11-mer peptides to HLA-A * 2402 molecules. <i>Immunogenetics</i> , 1996, 44, 233-241.	1.2	8
108	Peptide motifs of HLA-B58, B60, B61, and B62 molecules. <i>Immunogenetics</i> , 1995, 41, 165-168.	1.2	67

#	ARTICLE	IF	CITATIONS
109	HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. <i>Nature Medicine</i> , 1995, 1, 59-64.	15.2	771
110	Peptide motifs of HLA-B51, -B52 and -B78 molecules, and implications for Behcet's disease. <i>International Immunology</i> , 1995, 7, 223-228.	1.8	108
111	HLA-B*3501 peptide interactions: role of anchor residues of peptides in their binding to HLA-B* 3501 molecules. <i>International Immunology</i> , 1994, 6, 255-261.	1.8	55
112	Peptide motifs of HLA-A1,-A11,-A31, and-A33 molecules. <i>Immunogenetics</i> , 1994, 40, 238-241.	1.2	86
113	Identification of the gene encoding a novel HLA-B39 subtype Two amino acid substitutions on the β 2-sheet out of the peptide-binding floor form a novel serological epitope. <i>Human Immunology</i> , 1994, 41, 241-247.	1.2	11
114	Effect of single amino acid substitution at residue 167 of HLA-B51 on binding of antibodies and recognition of T cells. <i>Human Immunology</i> , 1994, 39, 211-219.	1.2	14
115	Expression of human minor histocompatibility antigen on cultured kidney cells. <i>European Journal of Immunology</i> , 1993, 23, 467-472.	1.6	7
116	HLA-B51 transgenic mice as recipients for production of polymorphic HLA-A, B-specific antibodies. <i>Immunogenetics</i> , 1993, 37, 139-42.	1.2	48
117	Molecular analysis of a novel HLA-A33 subtype associated with HLA-B44. <i>Tissue Antigens</i> , 1993, 41, 211-213.	1.0	19
118	DISCRIMINATION OF HLA-B5 CROSSREACTIVE GROUP ANTIGENS BY HUMAN ALLOSPECIFIC CTL CLONES. <i>Transplantation</i> , 1990, 49, 1164-1167.	0.5	17
119	Allo-class I-reactive CD4-CD8- T cell hybridomas recognize the conformational change of class I molecule resulting from the exchange of the β 3 domain. <i>European Journal of Immunology</i> , 1989, 19, 1861-1865.	1.6	1